Category - Markets

Roth Capital Partners initiated coverage on AxoGen (NASDAQ:AXGN) with a “buy” rating and target price of $14.50. The stock closed at $10 on March 3. “Driven by increased market awareness, surgeon education, clinical...

BTIG downgraded AtriCure (NASDAQ:ATRC) to “neutral,” citing a recent share price rally coupled with an unchanged outlook after the company’s Q4 report. The stock closed at $18.96 on March 3. AtriCure is a medical device...

Stifel raised its price target for Esperion Therapeutics (NASDAQ:ESPR) to $45 from $30. The stock closed at $29.33 on March 2. “We believe Amgen’s recent announcement that Repatha’s FOURIER trial resulted in a...

Analysts for H.C. Wainwright and Leerink raised their price targets for Aurinia Pharmaceuticals (NASDAQ:AUPH) after the company reviewed positive Phase 2b trial data for voclosporin in lupus nephritis (LN), which met...

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $9 from $7, but maintained its “hold” rating after the company reported fourth quarter results. The stock closed at $10.18 on March 2. STAAR...

Piper Jaffray launched coverage of MiMedx Group (NASDAQ:MDXG) with an “overweight” rating and $10 price target. The stock closed at $8.35 on March 2. MiMedx is the market leader for amniotic-based products used in wound...

Leerink analyst Paul Mattels is assuming coverage of Edge Therapeutics (NASDAQ:EDGE) with an “outperform” rating and $21 price target. The stock closed at $9.40 on March 2. “We view EDGE as a logical fit within our CNS...

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28. “Our focus is on the novel epigenetic regulator...

Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The...

Maxim Group initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and 12-month price target of $32. The stock closed at $22.10 on Feb. 23. Analyst Lauren Chung writes that 2017 could be a...